65 related articles for article (PubMed ID: 14718373)
1. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I.
Fuller M; Meikle PJ; Hopwood JJ
Glycobiology; 2004 May; 14(5):443-50. PubMed ID: 14718373
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of iduronic acid biosynthesis by ebselen reduces glycosaminoglycan accumulation in mucopolysaccharidosis type I fibroblasts.
Maccarana M; Tykesson E; Pera EM; Gouignard N; Fang J; Malmström A; Ghiselli G; Li JP
Glycobiology; 2021 Nov; 31(10):1319-1329. PubMed ID: 34192316
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of dermatan sulfate epimerase 1 decreased accumulation of glycosaminoglycans in mucopolysaccharidosis type I fibroblasts.
Maccarana M; Li B; Li H; Fang J; Yu M; Li JP
Glycobiology; 2024 Apr; 34(6):. PubMed ID: 38760939
[TBL] [Abstract][Full Text] [Related]
4. Secondary storage of dermatan sulfate in Sanfilippo disease.
Lamanna WC; Lawrence R; Sarrazin S; Esko JD
J Biol Chem; 2011 Mar; 286(9):6955-62. PubMed ID: 21193389
[TBL] [Abstract][Full Text] [Related]
5. α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial.
Harmatz P; Giugliani R; Martins AM; Hamazaki T; Kubo T; Kira R; Minami K; Ikeda T; Moriuchi H; Kawashima S; Takasao N; So S; Sonoda H; Hirato T; Tanizawa K; Schmidt M; Sato Y
Mol Ther; 2024 Mar; 32(3):609-618. PubMed ID: 38204164
[TBL] [Abstract][Full Text] [Related]
6. Insights into mucopolysaccharidosis I from the structure and action of α-L-iduronidase.
Bie H; Yin J; He X; Kermode AR; Goddard-Borger ED; Withers SG; James MN
Nat Chem Biol; 2013 Nov; 9(11):739-45. PubMed ID: 24036510
[TBL] [Abstract][Full Text] [Related]
7. Nanoemulsions as Gene Delivery in Mucopolysaccharidosis Type I-A Mini-Review.
Zapolnik P; Pyrkosz A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563175
[TBL] [Abstract][Full Text] [Related]
8. Negative electron transfer dissociation Fourier transform mass spectrometry of glycosaminoglycan carbohydrates.
Leach FE; Wolff JJ; Xiao Z; Ly M; Laremore TN; Arungundram S; Al-Mafraji K; Venot A; Boons GJ; Linhardt RJ; Amster IJ
Eur J Mass Spectrom (Chichester); 2011; 17(2):167-76. PubMed ID: 21719917
[TBL] [Abstract][Full Text] [Related]
9. A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I.
Le SQ; Kan SH; Clarke D; Sanghez V; Egeland M; Vondrak KN; Doherty TM; Vera MU; Iacovino M; Cooper JD; Sands MS; Dickson PI
Mol Ther Methods Clin Dev; 2018 Mar; 8():42-51. PubMed ID: 29159202
[TBL] [Abstract][Full Text] [Related]
10. Mucopolysaccharidosis Type I: The Importance of Early Diagnosis for Adequate Treatment.
Diogo R; Diogo L; Serra R; Almeida J; Oliveira A
Cureus; 2023 Dec; 15(12):e50595. PubMed ID: 38222174
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking analysis of a dermatan sulfate tetra-saccharide to human alpha-L-iduronidase.
Durán-Gutiérrez DP; López-Hidalgo M; Peña-Gomar IM; Zamorano-Carrillo A; Gómez-Esquivel ML; Castrejón-Flores JL; Reyes-López CA
Bioinformation; 2023; 19(12):1116-1123. PubMed ID: 38250526
[TBL] [Abstract][Full Text] [Related]
12. Development of a newborn screening tool for mucopolysaccharidosis type I based on bivariate normal limits: Using glycosaminoglycan and alpha-L-iduronidase determinations on dried blood spots to predict symptoms.
Langan TJ; Jalal K; Barczykowski AL; Carter RL; Stapleton M; Orii K; Fukao T; Kobayashi H; Yamaguchi S; Tomatsu S
JIMD Rep; 2020 Mar; 52(1):35-42. PubMed ID: 32154058
[TBL] [Abstract][Full Text] [Related]
13. Circulating anticoagulant glycosaminoglycans in mucopolysaccharidosis type I.
Tolar J; Orchard PJ; Key NS; Blazar BR
J Thromb Haemost; 2008 May; 6(5):893-5. PubMed ID: 18315551
[No Abstract] [Full Text] [Related]
14. Specific GAG ratios in the diagnosis of mucopolysaccharidoses.
Mathis D; Prost JC; Maeder G; Arackal L; Zhang H; Kurth S; Freiburghaus K; Nuoffer JM
JIMD Rep; 2024 Mar; 65(2):116-123. PubMed ID: 38444580
[TBL] [Abstract][Full Text] [Related]
15. A glycomic workflow for LC-MS/MS analysis of urine glycosaminoglycan biomarkers in mucopolysaccharidoses.
Nilsson J; Persson A; Vorontsov E; Nikpour M; Noborn F; Larson G; Blomqvist M
Glycoconj J; 2023 Oct; 40(5):523-540. PubMed ID: 37462780
[TBL] [Abstract][Full Text] [Related]
16. A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.
Mashima R; Ohira M; Okuyama T; Onodera M; Takada S
Sci Rep; 2023 May; 13(1):7865. PubMed ID: 37188686
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Multiple Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Severe and Attenuated Mucopolysaccharidosis-I.
Herbst ZM; Urdaneta L; Klein T; Fuller M; Gelb MH
Int J Neonatal Screen; 2020 Sep; 6(3):69. PubMed ID: 33123640
[TBL] [Abstract][Full Text] [Related]
18. From Translation to Protein Degradation as Mechanisms for Regulating Biological Functions: A Review on the SLRP Family in Skeletal Tissues.
Zappia J; Joiret M; Sanchez C; Lambert C; Geris L; Muller M; Henrotin Y
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31947880
[TBL] [Abstract][Full Text] [Related]
19. Fast, sensitive method for trisaccharide biomarker detection in mucopolysaccharidosis type 1.
Makino E; Klodnitsky H; Leonard J; Lillie J; Lund TC; Marshall J; Nietupski J; Orchard PJ; Miller WP; Phaneuf C; Tietz D; Varban ML; Donovan M; Belenki A
Sci Rep; 2018 Feb; 8(1):3681. PubMed ID: 29487322
[TBL] [Abstract][Full Text] [Related]
20. Validation of Urinary Glycosaminoglycans in Iranian patients with Mucopolysaccharidase type I: The effect of urine sedimentation characteristics.
Abdi M; Hakhamaneshi MS; Alaei MR; Azadi NA; Vakili R; Zamanfar D; Taghikhani M; Khatami S
Iran J Child Neurol; 2014; 8(4):39-45. PubMed ID: 25657769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
